Compare CX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CX | UTHR |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 20.3B |
| IPO Year | 1999 | 1999 |
| Metric | CX | UTHR |
|---|---|---|
| Price | $10.84 | $489.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $10.52 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 7.3M | 424.3K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 231.88 | 16.08 |
| EPS | 0.09 | ★ 26.38 |
| Revenue | ★ $15,869,840,000.00 | $3,128,400,000.00 |
| Revenue This Year | $2.25 | $13.64 |
| Revenue Next Year | $5.11 | $5.78 |
| P/E Ratio | ★ $11.48 | $18.55 |
| Revenue Growth | N/A | ★ 13.50 |
| 52 Week Low | $4.89 | $266.98 |
| 52 Week High | $11.05 | $492.62 |
| Indicator | CX | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 68.10 |
| Support Level | $10.00 | $470.13 |
| Resistance Level | $10.84 | $492.62 |
| Average True Range (ATR) | 0.27 | 10.72 |
| MACD | 0.04 | -0.53 |
| Stochastic Oscillator | 80.72 | 89.55 |
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.